Company intelligence / Profile preview

Jade Biosciences, Inc.

Sacramento, California, United Statesjadebiosciences.com ↗

Ownership: Public · JBIO
Development stage: Preclinical

Overview

Jade Biosciences is developing a pipeline of potentially best-in-class therapies for autoimmune diseases. Their lead asset JADE-001 targets the APRIL pathway for IgA nephropathy, with IND-enabling studies underway and first-in-human trials expected in the second half of 2025, with initial data anticipated in the first half of 2026.

Therapeutic areas: ImmunologyNephrology
Modalities: Monoclonal antibodies (mAbs)biologics
Industry: Biotech

Drug pipeline

5 assets

JADE101

4 more assets in the full pipeline.

Request access →

Partnerships

Assets licensed from Paragon Therapeutics

Financials

Market cap: $1.2B
Total revenue: $0
Enterprise value: $704.3M

Beyond the preview

Go deeper on Jade Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Jade Biosciences, Inc..

Explore the full profile